A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916
in adult patients with locally advanced or metastatic solid tumors.